“特朗普药房”正式上线，都有什么药？是否真降价？

Core Viewpoint - The TrumpRx initiative aims to allow American citizens to purchase prescription drugs directly from manufacturers at significantly discounted prices, bypassing traditional insurance systems and intermediaries [1][3]. Group 1: Pricing and Agreements - TrumpRx will enable the purchase of specific drugs at government-negotiated discount prices, potentially reducing prices by up to 600% for certain medications [3][4]. - The initiative is based on agreements with over a dozen pharmaceutical companies, including Amgen, Eli Lilly, Gilead, and Pfizer, under a "most favored nation" pricing policy [3][5]. - Pfizer has already announced that patients will be able to purchase its drugs at an average discount of 50% under this agreement, which will cover most primary care and some specialty brand medications [5]. Group 2: Economic Context - Trump highlighted that Americans have been paying the highest drug prices globally, subsidizing costs for other countries, with the U.S. consuming 13% of the world's prescription drugs despite only representing 4% of the global population [3]. - The government has agreed to forgo plans to impose tariffs on the pharmaceutical industry in exchange for discounted drug prices for Medicaid and direct consumer sales through TrumpRx [4]. Group 3: Criticism and Concerns - Some experts and Democratic lawmakers have expressed skepticism about the actual savings for consumers, questioning the clarity and feasibility of the TrumpRx plan [6][7]. - Concerns have been raised regarding the potential risks of expedited FDA approvals for participating drug companies, with warnings about the legality and safety of such processes [6]. - Critics argue that the focus on lowering "list prices" may overlook existing discounts and rebates that many Americans already benefit from, suggesting that the plan may not address the underlying issues in the healthcare system [6].